Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an update.
Oncolytics Biotech has appointed Andrew Aromando as Chief Business Officer to lead global business development and optimize the value of their clinical data for pelareorep, a promising cancer treatment. Aromando’s extensive experience in the life sciences industry, particularly in strategic planning and corporate development, is expected to accelerate Oncolytics’ clinical and business strategies, potentially enhancing its market position and delivering significant value to stakeholders.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is advancing its research in oncology, particularly in metastatic breast and pancreatic cancers, with pelareorep showing promising results in clinical trials. Oncolytics is working on combination clinical trials and aims to move towards registrational studies, with its products receiving Fast Track designation from the FDA.
YTD Price Performance: -21.21%
Average Trading Volume: 134,779
Technical Sentiment Signal: Sell
Current Market Cap: C$92.38M
See more insights into ONC stock on TipRanks’ Stock Analysis page.